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AT1R blockade reduces IFN-c production in lymphocytes in
vivo and in vitro.
Background. Type 1 angiotensin II (Ang II) receptor (AT1R)
signaling induces proinflammatory responses. Recent studies
suggest that T lymphocytes express AT1R; yet the effects of
Ang II binding to AT1R on T cells are poorly understood.
We examined the effect of AT1R blockade on release of the
proinflammatory cytokine, interferon-gamma (IFN-c) by hu-
man lymphocytes in vivo and in vitro.
Methods. We used an AT1R blocker losartan in a random-
ized clinical trial in kidney transplant recipients over a 12-
month period [AT1R blocker (N = 11) and control (N = 10)].
Peripheral blood lymphocytes, isolated from both cohorts,
were analyzed by enzyme-linked immunosorbent spot as-
says (ELISPOT) analyses and real-time reverse transcription-
polymerase chain reaction (RT-PCR) to enumerate IFN-c pro-
ducing T cells and IFN-c mRNA levels. The effects of AT1R
blockade in vitro were assessed using human alloreactive T cells
and an IFN-c producing human cytotoxic T-lymphocyte line.
Alloreactive T cells were treated with losartan or candesartan
and enzyme-linked immunosorbant assay (ELISA) was used
to measure IFN-c protein release. The cytotoxic T-lymphocyte
line also was AT1R blocker–treated prior to determining IFN-c
producing cells by intracellular cytokine staining.
Results. The AT1R blocker cohort had a significant decrease
in IFN-c producing peripheral blood lymphocytes (P ≤ 0.05 for
each time point) and IFN-c mRNA levels (P = 0.01 vs. con-
trol patients). Losartan also decreased IFN-c production (P <
0.001) in purified alloreactive T cells in vitro as did candesartan.
Moreover, Ang II amplified IFN-c generation (P < 0.05) in al-
loreactive T cells while AT1R blocker treatment inhibited Ang
II’s effect (P < 0.04). AT1R blocker treatment furthermore also
inhibited IFN-c production in the cytotoxic T-lymphocyte line.
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Conclusion. AT1R blockers may have a clinically relevant im-
munomodulatory role by blocking IFN-c production in T cells.
There is evidence that angiotensin II (Ang II) can affect
immune cell activity by amplifying chemokine expression
in macrophages, regulating dendritic cell differentiation,
and promoting lymphocyte proliferation [1, 2]. Ang II
affects peripheral blood mononuclear cells (PBMCs) in
a manner akin to that of cytokines, stimulating production
of tumor necrosis factor-a (TNF-a), transforming growth
factor-b (TGF-b), monocyte chemoattractant protein-1
(MCP-1), interleukin (IL)-1b , and tissue factor [3, 4]. Ang
II binding to Ang II type 1 receptor (AT1R) initiates
signal transduction that can transactivate other signaling
pathways, including the Janus kinase-signal tranducers
and activators of transcription (JAK-STAT) pathway that
can also result in cytokine production [5, 6]. This suggests
that blocking the effects of Ang II on immune cells could
blunt the inflammatory response that characterizes many
chronic systemic disorders.
Classic immunosuppressive agents fail to block all of
the mechanisms involved in immune cell activation and
function. As such, there is great advantage in identifying
other agents with anti-inflammatory and immunomodu-
latory properties that might be used either in combination
with current immunosuppressive agents or alone. AT1R
blockers represent one such group of medications. The-
oretically, they could modulate the effect of Ang II on
lymphocytes and alter their inflammatory phenotype.
T cells play a major role in mediating inflammatory
disorders by contributing to or causing tissue damage
through the release of interferon-c (IFN-c). Recently,
Shao et al [7] demonstrated that continuous infusion
of Ang II into rats significantly increased IFN-c lev-
els. This suggests that Ang II could be an important
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but heretofore, poorly examined hormonal factor driv-
ing IFN-c production in lymphocytes.
There is a paucity of data assessing the effects of AT1R
blockers on purified T cells or on T cells in vivo. We
examined these possible effects in vivo and in vitro us-
ing peripheral blood lymphocytes from kidney trans-
plant recipients, hypertensive patients, alloreactive T cells
derived from blood donors, and cells from a cytotoxic
T-lymphocyte line. We assessed IFN-c mRNA levels and
protein levels and proliferative responses in peripheral
blood lymphocytes from patients randomized to AT1R
blockers or no anti-Ang II treatment [no AT1R blocker
or angiotensin-converting enzyme (ACE) inhibitor] as
part of their medical therapy. We used a human cytotoxic
T-lymphocyte line and human alloreactive T cells as in
vitro models to confirm in vivo findings that AT1R block-
ade significantly reduced IFN-c expression. As these are
indirect observations of Ang II’s effect on peripheral
blood lymphocytes, we also determined the direct effect
of Ang II addition on IFN-c production in alloreactive
T cells. These data, in aggregate, indicate a role for Ang II
in modulating T-cell IFN-c production.
METHODS
Patient population
The University of Wisconsin Institutional Review
Board approved the study, enrollment process, and pro-
tocol. Kidney transplant patients (study subjects) with
mild allograft dysfunction (serum creatinine ≥0.3 mg/dL
above baseline at 6 months after transplant) were ran-
domized to treatment with either losartan (25 to 100 mg
daily by mouth) as part of their medical regimen or
with other types of antihypertensive agents (e.g., calcium
channel blockers), excluding agents that serve as AT1R
blockers (Table 1). The variable losartan dose was based
on blood pressure response. Changes in kidney func-
tion were determined by serum creatinine and estimated
glomerular filtration rate (eGFR) using the second equa-
tion derived by Nankivell et al [8]. Neither group received
ACE inhibitors. Study subjects were also maintained on
a standard immunosuppressive regimen [corticosteroids
5 to 10 mg orally daily; mycophenolate mofetil (MMF)
500 to 1000 mg orally twice a day; plus a calcineurin
inhibitor (cyclosporine A with target levels 100 to
150 ng/mL or tacrolimus with target levels 2 to 5 ng/mL
or sirolimus with target levels 5 to 10 ng/mL)]. Another
group of individuals who were not transplant recipients
but who had hypertension (N = 5) were placed on losar-
tan alone as treatment for their blood pressure and kid-
ney condition. These individuals were then studied in a
manner as described prior to losartan use (t = 0) and at
3 months after losartan treatment for IFN-c protein and
mRNA production and proliferative response.
Table 1. Patient demographics for individuals in the AT1R blocker
clinical trial
AT1R P
Category Control blocker value
Number 10 11
Gender M/F 6/4 7/4 NS
Age years 46.2 ± 13.8 52.1 ± 10.4 NS
Calcineurin inhibitor/sirolimus 7/3 7/4 NS
Estimated glomerular filtration
rate (mL/min) at study entry
61.3 ± 6.8 64.7 ± 10.4 NS
History of biopsy-proven
rejection
2 2 NS
Peripheral blood lymphocytes
Whole blood was taken from individuals enrolled in
the study, washed in saline solution and treated with ACK
lysis buffer [150 mmol/L NH4Cl, 10 mmol/L KHCO3,
and 0.1 mmol/L Na2 ethylenediaminetetraacetic acid
(EDTA), pH 7.3] to lyse red blood cells. Samples were
then centrifuged and cells were resuspended at 1.5 × 106
cells per mL in 10 mL complete RPMI media (RPMI-
1640) (BioWhitaker, Walkersville, MD, USA), supple-
mented with fetal calf serum (FCS) (Sigma Aldrich,
St. Louis, MO, USA), 2 mmol/L L-glutamine
(BioWhitaker), 50 lmol/L 2-b-mercaptoethanol (Sigma
Aldrich), 100 U/mL penicillin, and 100 lg/mL strepto-
mycin sulfate (Sigma Aldrich).
Proliferation assay
Purified peripheral blood lymphocytes were plated at
1 × 106 cells per well in six-well plates followed by incuba-
tion for 3 days at 37◦C with immobilized anti-CD3e mon-
oclonal antibody (Immunotech, Marseille, France) and
antihuman CD28 monoclonal antibody (BD PharMin-
gen, San Diego, CA, USA) at 2.5 lg and 1 lg, respec-
tively. Control wells were exposed to phosphate-buffered
saline (PBS). T cells were assessed by flow cytometry af-
ter 72 hours of stimulation and found to contain >90%
CD3+ cells. After harvesting, control and stimulated cells
were plated at 1 × 105 cells per well in triplicate in a
96-well plate. Media containing 0.5 lCu [3H]-thymidine
(Amersham Bioscience, Piscataway, NJ, USA) was added
to each well, plates were then incubated overnight at
37◦C and analyzed for [3H]-thymidine incorporation de-
termined using a Packard TopCount NXT Scintillation
plate reader. The proliferation index was calculated as
previously described [9]. The  proliferation index was
calculated by assessing the difference between the pro-
liferation index at baseline and the proliferation index at
various time points indicated.
Enzyme-linked immunosorbent spot assays
(ELISPOT) assay
The CD3/CD28-stimulated cells that remained after
setting up the proliferation assay were used for ELISPOT
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analysis. ELISPOT assays were conducted according to
the manufacturer’s directions (Cellular Technology, Ltd.,
Cleveland, OH, USA). Cells were resuspended to 3 × 105
per mL and serial two fold dilutions were made across 96-
well plates coated with anti-IFN-c or anti-IL-5 antibody.
Plates were incubated for 2 days at 37◦C, washed three
times with PBS and three times with PBS/Tween (0.1%).
Biotinylated secondary detection antibodies (OptEIA
IFN-c and IL-5 obtained from the aforementioned kits)
were diluted in 1% bovine serum albumin (BSA)/PBS
before addition to the wells. The plates were incubated
for 24 hours, washed four times with PBS/Tween, and
streptavidin alkaline phosphatase (Dako #D0396) (Dako,
Glostrup, Denmark) was added to the plates for 2 hours.
The plates were washed with PBS, substrate was added,
developed for 15 to 60 minutes, and then washed with
distilled water to stop the reaction and allowed to air dry.
Preselected wells were incubated with phytohemagglutin
as a positive control (10 lg/mL), similar to studies from
Gebauer et al [10]. The final volume for all assay wells
was 200 lL/well. Plates were then scanned and analyzed
by Immunospot® Software (CTL Technologies).
Real-time polymerase chain reaction (PCR) of
peripheral blood lymphocyte samples
Total RNA was extracted as described [11]. cDNA,
obtained from sample RNA (Roche First Strand cDNA
Synthesis Kit) (Roche, Indianapolis, IN, USA), was then
used for PCR reactions. PCR reactions were prepared
using 2× TaqManTM Master Mix, cDNA template and
RNAse-free water, and 20× Target assay mix. Nontem-
plate samples were run as controls. Samples were also
assayed for 18S ribosomal RNA as an internal control.
Assays contained 12.5 ng sample cDNA plus primers and
probe at concentrations of 0.9 lmol/L and 0.25 lmol/L,
respectively. Cycle conditions were 50◦C for 2 minutes
then 10 minutes at 95◦C then 40 cycles consisting of 15
seconds at 95◦C (denature) followed by 1 minute at 60◦C
for annealing and extension. All samples were assayed
in quadruplicate. We have used this methodology suc-
cessfully to compare relative mRNA levels across tissue
samples in large-scale studies [11].
Generation of human alloreactive T cells
Blood was collected from volunteers using a proto-
col approved by the Institutional Review Board at Texas
Tech University Health Sciences Center. Human allore-
active T cells were generated in mixed lymphocyte re-
actions using irradiated allogeneic stimulator cells. T-cell
purity was determined to be greater than 90% based on
flow cytometry and staining with anti-CD3e monoclonal
antibody (UCHT1) (BD PharMingen).
Effect of Ang II and AT1R blocker on IFN-c production
in human alloreactive T cells
Alloreactive T cells (1 × 106 cells/well) were added
to a 48-well plate and stimulated using either irradi-
ated human leukocyte antigen (HLA) mismatched stim-
ulator cells (2 × 105 cells/well) or on plates containing
immobilized anti-CD3 antibody (UCHT1). Cells were
cultured in the absence of any additions (positive con-
trol), in the presence of Ang II (Sigma, St. Louis, MO,
USA) at 10 nmol/L and 0.1 nmol/L, in the presence of
10 lmol/L candesartan (CV-11974), or in the presence of
10 and 0.1 nmol/L Ang II concentrations plus 10 lmol/L
candesartan. Candesartan was kindly provided by As-
traZeneca (Wilmington, DE, USA). At 24 hours, culture
supernatant was harvested and IFN-c was detected by
enzyme-linked immunosorbant assay (ELISA) accord-
ing manufacturer’s instructions (BD PharMingen).
Antigen-specific stimulation of the anti-p53 cytotoxic
T lymphocytes
An IFN-c producing human cytotoxic T-lymphocyte
line [12] was kindly provided by Dr. Albert De Leo
(University of Pittsburgh, PA, USA). This cytotoxic
T-lymphocyte line was used for characterizing the ef-
fects of AT1R blockade on IFN-c expression. The cyto-
toxic T-lymphocyte line was maintained using irradiated
HLA-A2 matched feeder cells pulsed with the p53 pep-
tide (aa 264–272 LLGRNSFEV) and supplemented with
10 U/mL of human recombinant IL-2 (rhIL-2). Cells were
grown in six-well plates at 106 cells per well and stimulated
using an irradiated HLA-A2 positive lymphoblastoid cell
line at 1 × 104/well pulsed with 10 lg/well of p53 peptide.
Intracellular staining
Cells from the human cytotoxic T-lymphocyte line (2 ×
105/well) were added to a 96-well plate and stimulated
with irradiated lymphoblastoid cell line as described
above in the absence (positive control) or presence of 10
lmol/L candesartan. At 96 hours, cells were harvested
and intracellular cytokine staining was performed per
protocol. Intracellular staining of human cytotoxic
T-lymphocyte controls (untreated/unstimulated and
untreated/stimulated) and experimental cells
(candesartan-treated/stimulated) was performed
using IL-4 [anti-IL-4-fluorescein isothiocyanate (FITC)-
conjugated, mouse IgG2b,j] (#34019.111) (R&D
Systems, Minneapolis, MN, USA)and IFN-c (anti-IFN-
c-phycoerythrin-conjugated, mouse IgG2a,j] (#25718.11)
(R&D Systems) specific antibodies per the protocol
provided by BD PharMingen.
Statistical methodology
Differences between groups were assessed using Stu-
dent t test and analysis of variance (ANOVA). Statistical
Weidanz et al: AT1R blockers in T-cell function 2137
analyses were performed using SigmaStat for Windows
version 3.0 (SPSS Inc., Chicago, IL, USA). Data are re-
ported as mean ± SD.
RESULTS
Study population
Twenty-one kidney transplant recipients were ran-
domly divided into two groups. One group received losar-
tan as part of their high blood pressure regimen; the other
did not. Neither group received ACE inhibitors. Kidney
function, as assessed by mean serum creatinine and eGFR
[8], was comparable between the two groups as were the
number of acute rejection episodes (data not shown).
Patients in both cohorts were given the same immuno-
suppressive agents that included MMF and calcineurin
inhibitors during the time course of the study.
Blood pressure and eGFR values were similar in both
groups during the study time course (data not shown).
Proteinuria declined in the AT1R blocker cohort (spot
urine protein/creatinine ratio study entry 1.9 ± 0.8 g/L;
12-month spot urinary protein/urinary creatinine 1.1 ±
0.45 g/L) (P = 0.016). There was a slight (nonsignificant)
reduction in the urinary protein/urinary creatinine ratio
in the control cohort [study entry 2.1 ± 1.1 g/L; not sig-
nificant (NS) vs. losartan study entry; 12 months 1.66 ±
0.93 g/L].
ELISPOT analyses for peripheral blood lymphocyte gen-
eration of IFN-c
Anti-Ang II therapy may be renoprotective in the set-
ting of chronic allograft nephropathy (CAN) [12]. Given
that alloimmune factors contribute to CAN, it is logical
to consider that therapies in that setting that are success-
ful may have salutary effects on immune responses. We
therefore examined the ability for AT1R blockers to in-
hibit T-cell–mediated IFN-c production. This cytokine,
produced primarily by T cells and natural killer (NK)
cells, has effector functions that include activation of
macrophages and endothelial cells. Peripheral blood lym-
phocytes isolated from patients were assayed for IFN-c
expression as described. Baseline values were not signifi-
cantly different between treatment groups (spots per 1 ×
106 cells at study entry AT1R blocker 3654 ± 1471; con-
trol 3803 ± 1255; NS) The AT1R blocker cohort demon-
strated a significant reduction in IFN-c producing cells
[(spots per 1 × 106 cells) 3 months AT1R blocker 4127 ±
1289; control 6231 ± 1834 (P = 0.01); 6 months AT1R
blocker 3899 ± 1508; control 5124 ± 2253 (P = 0.05);
9 months AT1R blocker 3845 ± 1493; control 6889 ±
1863 (P < 0.001); 12 months AT1R blocker 4276 ± 1456;
control 6471 ± 1621 (P < 0.05)] (Fig. 1).
We also examined whether AT1R blocker treatment
resulted in a shift from a Th1 to a Th2 phenotype by
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Fig. 1. ELISPOT results. This bar graph demonstrates the ELISPOT
results for interferon-c (IFN-c) comparing the nonangiotenin II type
1 receptor (AT1R) blocker (ARB) treatment group versus the AT1R
blocker cohort. ELISPOT assays were performed as described in the
Methods section. Values shown are mean ± SD of spots per 1 × 106
cells. The AT1R blocker cohort had significant fewer spots at the time
points tested.
assaying for IL-4 and IL-5 expression. There was no
demonstrable effect on IL-4 or IL-5 production follow-
ing institution of AT1R blocker therapy (data not shown)
suggesting that AT1R blockers specifically inhibited IFN-
c production. The effect of AT1R blocker therapy was
not restricted to kidney transplant patients alone. To de-
termine whether the affect of losartan on T cells was
specific for renal transplant recipients, we isolated pe-
ripheral blood lymphocytes from hypertensive patients
(N = 5) without renal disease (serum creatinine 1.2 ±
0.3 mg/dL) or any other form of solid organ transplanta-
tion. Each individual (three women and one man; mean
age 47 ± 7 years) received losartan 50 mg daily as treat-
ment for hypertension during the time period noted.
Mean systolic blood pressure was 138 ± 9 mm Hg on
treatment and mean diastolic blood pressure was 82 ± 4
mm Hg. Samples were obtained from these individuals
at baseline and then after 3 months of therapy. When we
examined this set of nontransplant recipients with hyper-
tension also treated with losartan, ELISPOT values at 3
months of treatment were not significantly different from
the transplant AT1R-treated patients (spots per 1 × 106
cells 4716 ± 1003) (P < 0.05 vs. control) (NS vs. AT1R
blocker transplant).
Real-time PCR for IFN-c mRNA levels
We assayed IFN-c mRNA levels using real-time PCR
in peripheral blood lymphocyte samples from patients
treated with AT1R blockers versus control patients.
AT1R blocker treatment was associated with a signifi-
cant reduction in IFN-c mRNA levels from peripheral
blood lymphocytes. Figure 2 shows IFN-c mRNA levels
from real-time PCR results on peripheral blood lympho-
cytes isolated from AT1R blocker–treated versus con-
trol groups at early (3 months) and late (12 months)
time points. The AT1R blocker–treated cohort had a
significant reduction in peripheral blood lymphocyte
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Fig. 2. Reverse transcription-polymerase chain reaction (RT-PCR)
interferon-gamma (IFN-c) mRNA. Real-time PCR was performed to
determine levels of IFN-c mRNA described in the Methods section.
Data were obtained from analysis of control versus angiotensin II type
1 receptor (AT1R) blocker (ARB)–treated subject peripheral blood
lymphocyte samples. All individuals provided samples for analysis for
baseline values. For the 3-month samples, ten control and ten AT1R
blocker–treated samples were analyzed. For the 12-month samples, ten
control and ten AT1R blocker–treated samples were analyzed. Data
shown are mean ± SE. ∗P < 0.05 vs. baseline values; +P < 0.04 vs.
control.
IFN-c mRNA levels compared to the control cohort at
each time point (P < 0.04). To examine whether losartan’s
effects were specific for kidney transplant patients, we
also assayed peripheral blood lymphocytes from five pa-
tients with hypertension prior to treatment and 3 months
after treatment with losartan. Losartan also decreased
peripheral blood lymphocyte IFN-c mRNA levels after
3 months of treatment in the nontransplant patient subset
(35 ± 12% reduction) (P = 0.041 vs. time 0).
Peripheral blood lymphocyte proliferation indices
We then examined the short- and long-term conse-
quence of losartan therapy in vivo on T-cell prolifer-
ation. There was no significant difference in prolifera-
tion indices at study entry for individuals in the AT1R
blocker versus control cohort (NS) (Fig. 3) The AT1R
blocker cohort demonstrated a significant reduction in
CD3-stimulated peripheral blood lymphocyte prolifera-
tion indices at 6, 9, and 12 months of losartan treatment
versus the control group [6 months 69 ± 47% decrease)
(P < 0.005); 9 months 52 ± 21% decrease (P < 0.05); and
12 months 53 ± 31% decrease (P = 0.032)] (Fig. 3).
We also analyzed the change in proliferation from base-
line ( proliferation index). The AT1R blocker cohort
had a significant reduction in the  proliferation index
at each time point evaluated (P < 0.04 at 3, 6, 9, and 12
months) (data not shown).
In vitro effects of losartan on IFN-c production in purified
human alloreactive effector T cells
To determine whether the effects of losartan were
T-cell specific, purified human alloreactive effector T
cells were incubated with and without losartan (0.1 to
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Fig. 3. Lymphocyte proliferation indices. Peripheral blood lympho-
cyte samples were harvested from individuals in each study cohort
and treated as described in the Methods section to determine whether
chronic angiotenin II type 1 receptor (AT1R) blocker (ARB) treatment
altered lymphocyte proliferation. The lymphocyte proliferation index
was calculated as described in the Methods section. Chronic AT1R
blocker treatment led to a decrease in peripheral blood lymphocyte
proliferation. Data shown are mean ± SD.
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Fig. 4. Dose response effect of losartan on purified human alloreactive
effector T cells. Human allogeneic effector T cells were generated in
a mixed lymphocyte reaction, rested, purified using anti-CD3 antibody
tagged magnetic beads (Miltenyi), washed, and restimulated with im-
mobilized anti-CD3 monoclonal antibody (UCHT-1) in the presence or
absence of losartan (0.1 to 10 lmol/L). Cell supernatants were sampled
after 24 hours and assayed for interferon-c (IFN-c) by enzyme-linked
immunosorbent assay (ELISA). The addition of losartan showed a sig-
nificnat dose dependent reduction of IFN-c production (N = 4 from
two donors) P < 0.001).
10 lmol/L concentration) and stimulated with immobi-
lized anti-CD3 monoclonal antibody. Losartan treatment
led to a significant dose-dependent reduction in IFN-c
production by human alloreactive T cells (Fig. 4). This
suggested a losartan-specific effect on effector T-cell func-
tion.
In vitro effect of Ang II blockade on IFN-c production
in a cytotoxic T-lymphocyte line
To further define whether the reduction in IFN-c pro-
duction in T cells observed with losartan was mediated
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through specific blockade of AT1R, we expanded our
studies with AT1R blocker treatment to include candesar-
tan CV-11974. We used an IFN-c producing cytotoxic
T-lymphocyte line in stable culture to assess the direct ef-
fects of candesartan on IFN-c generation. The cytotoxic
T-lymphocyte line was NK and T-cell free as determined
by staining for CD56 (>1% of cells stained positive) and
there was no evidence of NK cell-specific cytotoxicity
(data not shown). IFN-c production was evaluated by
intracellular cytokine staining and flow cytometry.
Minimal nonspecific staining of the cytotoxic T-cell
lymphocyte line was observed with isotype antibody
controls. Eighty-seven percent of the gated T-cell pop-
ulation present in the cytotoxic T-lymphocyte line
produced IFN-c (Fig. 5A) after peptide stimulation. Un-
stimulated cells showed little production of either cy-
tokine (Fig. 5A). Candesartan (10 lmol/L) significantly
decreased the number of IFN-c producing cells (> 90%
reduction) to a level seen in the unstimulated T-cell popu-
lation (N = 3) (Fig. 5A) without any significant change in
IL-4 production. Candesartan also had no effect on cell
viability as assessed by trypan blue exclusion after any
period of incubation or in a 3-[4, 5] dimethylthiazol-2,5-
diphenyltetrazolium bromide (MTT) viability assay read
after 96 hours (data not shown).
AT1R blockade of human alloreactve effector T cells
leads to reduction in IFN-c production
We then conducted experiments with candesartan in
human alloreactive effector T cells. These cells (55%
CD4+ and 45% CD8+), when stimulated with irradi-
ated HLA mismatched stimulator cells for 96 hours in the
presence of 10 lmol/L candesartan elaborated less IFN-c
secretion compared to untreated (control) (N = 3) (P <
0.001) (Fig. 5B). These findings corroborated both the in
vivo results and the decrease in IFN-c production in the
cytotoxic T-lymphocyte line following AT1R blockade.
Ang II induction of IFN-c production in human
alloreactive effector T cells
Stimulation of alloreactive effector T cells with irra-
diated HLA mismatched stimulator cells for 24 hours
in the presence of Ang II (0.1 nmol/L) led to a signifi-
cant increase in IFN-c production compared to untreated
cells (control) (N = 3) (P < 0.05) (Fig. 5C). To deter-
mine whether Ang II induction of IFN-c was mediated
via AT1R, effector cell cultures were coincubated with
both Ang II and candesartan. Candesartan significantly
reduced the Ang II–mediated increase in IFN-c produc-
tion in the supernatant at 24 hours (N = 3) (P < 0.04 for
10 nmol/L Ang II vs. 10 nmol/L Ang II + candesartan)
(N = 3) (P < 0.02 for 0.1 nmol/L Ang II vs. 0.1 nmol/L
Ang II + candesartan). This suggested that the Ang II ef-
fect on IFN-c production occurred via AT1R on effector
T cells (Fig. 5C).
DISCUSSION
In vitro studies have suggested that Ang II exerts ef-
fects on lymphocytes [13, 14]. We examined a clinical
population for in vivo evidence of an AT1R blocker’s abil-
ity to decrease T-cell production of IFN-c. We evaluated
both short-term (3 months) and long-term (12 months)
affects of AT1R blocker treatment on IFN-c production
in peripheral blood lymphocytes and found a significant
reduction in the number of IFN-c producing cells in the
AT1R blocker–treated cohort compared to control sub-
jects. Our findings include a limited analysis of peripheral
blood lymphocytes derived from hypertensive individu-
als prior to and 3 months after treatment with losartan
that parallel our observations for a reduction of periph-
eral blood lymphocyte IFN-c production and prolifera-
tion after AT1R blockade in kidney transplant recipients.
We then conducted in vitro tests to assess AT1R blocker
effects on T-cell IFN-c generation to confirm our in vivo
observations. We used a human cytotoxic T-lymphocyte
line and physiologically relevant human alloreactive ef-
fector T cells for these studies and demonstrated Ang
II–mediated induction of IFN-c. AT1R blockers signif-
icantly inhibited Ang II–mediated IFN-c production in
these cells, suggesting that AT1R mediated this effect.
The similar results in vivo and in vitro show that AT1R
blockers in general exert an immunomodulatory function
by altering IFN-c levels in T cells.
Our kidney transplant recipients represent an intrigu-
ing population in which to investigate the effects of
AT1R blockers. Transplantation, by its very nature, of-
ten evokes lymphocyte and, even more specifically, T-
cell–mediated responses. Therefore, it is interesting that
T-cell–mediated injury in kidney tissue can be linked
to renin-angiotensin system activity independent of any
hemodynamic effects [13]. It follows logically that AT1R
blockade could have beneficial effects under conditions
of inappropriate T-cell activation. Nataraj et al [14] found
that Ang II, acting through AT1R, stimulated lymphocyte
proliferation via activation of calcineurin phosphatase
and suggested that AT1R blockers could be used in con-
junction with calcineurin inhibitors to achieve an additive
immunomodulatory effect. The current findings expand
upon these observations by demonstrating an additive
immunomodulatory response in vivo in the presence of
AT1R blockade, exemplified by a reduction in IFN-c gen-
eration.
These data also extend the observations by Fernandez-
Castelo et al [15]. They demonstrated a direct association
between Ang II and IFN-c production in lymphocytes in
vitro. We used similar concentrations of Ang II in our
studies. However, we did not identify the biphasic effect
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Fig. 5. Effects of interferon-c (INF-c) pro-
duction. (A) Candesartan blocks IFN-c pro-
duction in a human cytotoxic T-lymphocyte
line. Intracellular cytokine staining and flow
cytometric analysis of a human cytotoxic T-
lymphocyte line specific for the p53 264-272
peptide was carried out after 4 days of antigen-
specific stimulation in the presence or ab-
sence of the angiotensin II (Ang II) type 1
receptor (AT1R) blocker (ARB) candesar-
tan (10 lmol/L). Unstimulated cells received
neither peptide nor candesartan during the
growth period. Cells were fixed, permeabi-
lized, and stained with antibodies specific for
human IFN-c (labeled with phycoerythrin)
and interleukin (IL)-4 [labeled with fluores-
cein isothyiocyanate (FITC)]. These findings
are representative of three experiments. (B)
Candesartan inhibits IFN-c production by hu-
man allogeneic T cells. Human alloreactive
effector T cells were generated in a mixed
lymphocyte reaction, rested and restimulated
in the presence or absence of candesartan.
Cell supernatants were sampled after 4 days
and assayed for IFN-c by enzyme-linked im-
munsorbent assay (ELISA). The addition of
candesartan significantly inhibited IFN-c pro-
duction (N = 3) (P < 0.001). (C) Ang II in-
duces IFN-c production in human alloreac-
tive T cells. Human alloreactive T cells were
used to determine Ang II’s role in IFN-c pro-
duction after 24 hours in culture. T cells were
stimulated with irradiated human leukocyte
antigen (HLA) mismatched stimulator cells
in the presence of Ang II or Ang II + can-
desartan. The addition of 0.1 nmol/L Ang II
significantly stimulated production of IFN-c
(P < 0.05). The addition of 10 lmol/L can-
desartan to wells that received either 0.1 or 10
n,ol/L Ang II significantly blocked the Ang II
effect on IFN-c production (P < 0.02 and P <
0.04, respectively).
that they reported. This is likely due to differences in T-
cell purity, disparities in CD4+ and CD8+ T-cell ratios
and an altered activation state of the cells in our stud-
ies. There is also a striking corollary set of data recently
described by Shao et al [7], comparable to our findings.
They showed that rat splenic T cells manifested a 30% in-
crease in IFN-c production following Ang II treatment.
This compares favorably to increase in IFN-c secretion
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we observed in response to Ang II. While these Ang II
effects may appear modest in vitro, the same group noted
potent effects of Ang II on IFN-c production in vivo, sup-
porting a physiologic role for Ang II. Moreover, AT1R
blocker treatment in vivo reduced Ang II–induced T-cell
IFN-c production in the animals.
We focused primarily on responses in human cells.
Even in the in vitro studies, we attempted to be highly
specific in examining IFN-c generation from both a cyto-
toxic T-lymphocyte line and alloreactive effector T cells
in an effort to substantiate the findings from the pe-
ripheral blood lymphocyte studies. Using both cell sets
also afforded us the opportunity to determine if losartan
had direct effects on T cells. Moreover, we could assess
whether candesartan’s effects on T-cell IFN-c production
was AT1R-specific. The fact that AT1R blockers specifi-
cally decreased IFN-c production in vitro in the absence
of shift in Th2-type cytokine production suggests that
AT1R are immunomodulatory receptors.
Losartan and candesartan vary slightly in terms of their
affinity for AT1R and their duration of antagonism [16].
Candesartan, unlike losartan, does not appear to inter-
act with the intracellular form of the angiotensin recep-
tor or the thromboxane receptor [17, 18]. Thus, it may
be more specific for in vitro testing. The significant ef-
fect of candesartan treatment on IFN-c production in the
cytotoxic T-lymphocyte studies and the strong effects of
both AT1R blockers on alloreactive effector T cells sug-
gest that the primary effect of losartan on the periph-
eral blood lymphocytes was due to AT1R antagonism.
Intriguingly, our observations using two different AT1R
blockers and the finding that olmesartan reduced IFN-c
generation in T cells in treated rats [7] collectively sup-
port a general mechanism of action for AT1R blockers to
down-modulate T-cell production of IFN-c.
CONCLUSION
These studies suggest that AT1R blocker treatment al-
ters IFN-c generation in peripheral blood lymphocytes
both in vitro and in vivo. Several caveats to our study
are noteworthy in the context of this conclusion. We
acknowledge there is no clinical evidence of immunosup-
pression with AT1R blockers in people with hypertension
or receiving immunosuppression. We also recognize that,
despite the in vivo findings, the in vitro concentrations
employed may not represent what occurs clinically. Fur-
ther, we examined a small number of patients in each
cohort of the clinical investigation. Although serial sam-
pling, the lack of significant demographic differences be-
tween the cohorts, and the ability to use subjects as their
own controls afforded us a degree of confidence in the re-
sulting data, we recognize the possibility of a error. Yet,
other studies of a similar nature and size have used the
same methodologies. In addition, ex vivo manipulation
of cells could alter their inherent properties. Nonethe-
less, the measured intraindividual responses still suggest
a specific AT1R blocker effect that crossed cohorts. The
results are descriptive as befits a translational clinical trial
in humans, and for that reason, it is important to recog-
nize that the in vitro investigations help to corroborate
the in vivo studies. While newer mechanisms involving
Ang II and cytokines continue to be described [19], it
is important to recognize that defining such mechanisms
in vivo is difficult. Nevertheless, these data suggest that
AT1R blockers may have immunomodulatory functions
as a component of their receptor antagonism.
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